In vivo biodistribution and lifetime analysis of Cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging

Molecular Imaging

Volumn 7, Issue 6, 2008, Pages 272-282

  Biffi, Stefania ^a   Garrovo, Chiara ^b   Macor, Paolo ^b   Tripodo, Claudio ^b   Zorzet, Sonia ^b   Secco, Erika ^b   Tedesco, Francesco ^b   Lorusso, Vito ^b  

^a CBM   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIODISTRIBUTION; BIOLOGIC ACTIVITIES; ENDOVENOUS INJECTION; EX-VIVO; IMAGING EXPERIMENTS; IMMUNOHISTOCHEMISTRY; IN-VITRO; IN-VIVO; INTRAPERITONEAL; INTRAPERITONEAL INJECTIONS; LIFETIME ANALYSIS; LONG LASTING; LYMPHOID MALIGNANCIES; NEAR INFRA RED; NEAR-INFRARED OPTICAL IMAGING; OPTICAL IMAGING; OPTICAL IMAGING ANALYSIS; TIME DOMAIN; TUMOR CELLS; TUMOR TISSUES; TUMOR UPTAKE; TUMOR XENOGRAFTS;

BEARINGS (STRUCTURAL); FLUORESCENCE; INFRARED DEVICES; MONOCLONAL ANTIBODIES; OPTICAL IMAGE STORAGE; PROBES; TIME DOMAIN ANALYSIS;

TUMORS;

CARBOCYANINE; CY5.5 CYANINE DYE; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL; ARTICLE; BINDING SITE; CANCER TRANSPLANTATION; CELL DIVISION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE ABSORPTION; LYMPH NODE; LYMPHOMA; METHODOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CARBOCYANINES; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL ABSORPTION; LYMPH NODES; LYMPHOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 65249147251     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2008.00028     Document Type: Article

References (16)

1. Sampath L, Kwon S, Ke S, et al. Dual-labeled trastuzum ab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007;48:1501-10.
2. Xu H, Baidoo K, Gunn AJ, et al. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 2007;50:4759-65.
3. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygenand nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
4. Hassan M, Riley J, Chernomordik V, et al. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 2007;6:229-36.
5. Bloch S, Lesage F, Mcintosh L, et al. Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J Biomed Opt 2005;10:054003.
6. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology 1998;12:1763-9.
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
8. Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006;33:S2-14.
9. Schuna AA. Rituximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2007;27:1702-10.
10. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-63.
11. Lam S, Lesage F, Intes X. Time-domain fluorescent diffuse optical tomography: analytical expressions. Optics Express 2005;13:2263-75.
12. Abulrob A, Brunette E, Slinn J, et al. In vivo time domain optical imaging of renal ischemia-reperfusion injury: discrimination based on fluorescence lifetime. Mol Imaging 2007;6:304-14.
13. Macor P, Secco E, Zorzet S, et al. An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. Curr Pharm Des 2008;14:2023-39.
14. Baio G, Fabbi M, de Totero D, et al. Magnetic resonance imaging at 1.5 T with immunospecific contrast agent in vitro and in vivo in a xenotransplant model. MAGMA 2006;19:313-20.
15. 15.Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non- Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276-82.
16. 18F-FDG in rodents. J Nucl Med 2007;48:277-87.